Rituximab | Cyclophosphamide | P | |
---|---|---|---|
PFT | |||
FVC evolution at 6 mos (% of baseline) | +4.5 (−14, 34), n = 22 | +4 (−35, 65), n = 33 | 0.46 |
cDLCO evolution at 6 mos (% of baseline) | +2 (−12, 19), n = 21 | +3 (−14, 28), n = 32 | 0.86 |
FVC evolution at 1 yr (% of baseline) | +7 (−9, 30), n = 24 | +4 (−19, 37), n = 19 | 0.18 |
cDLCO evolution at 1 yr (% of baseline) | +1 (−10, 21), n = 24 | +4 (−12, 34), n = 17 | 0.61 |
FVC evolution at 2 yrs (% of baseline) | +7 (−12, 34), n = 16 | +5 (−13, 27), n = 8 | 0.73 |
cDLCO evolution at 2 yrs (% of baseline) | +5 (−10, 57), n = 16 | +3 (−4, 20), n = 9 | 0.78 |
CT scan, n | |||
Improvement of ILD extension | 11/24 | 8/30 | 0.16 |
Worsening of ILD extension | 1/24 | 8/30 | 0.03 |
Additional treatments, n | |||
AZA | 6 | 14 | |
MTX | 3 | 2 | |
MMF | 5 | 12 | |
CalciNI | 1 | 2 | |
IVIG | 2 | 7 | |
None | 13 | 0 | |
Adverse events, % (n) | |||
All infections | 36 (10) | 38 (13) | 1.0 |
Severe infections | 4 (1) | 12 (4) | 0.37 |
Death | 4 (1) | 3 (1) | 1.0 |
Values are median (Q1–Q3) unless otherwise specified. AZA: azathioprine; CalciNI: calcineurin inhibitor (cyclosporine or tacrolimus); cDLCO: corrected diffusing lung capacity for carbon monoxide; CT: computed tomography; FVC: forced vital capacity; ILD: interstitial lung disease; IVIG: intravenous immunoglobulin; MTX: methotrexate; MMF: mycophenolate mofetil; PFT: pulmonary function tests.